Clinical Trials Browser

Terminated × INDUSTRY × Albumin-Bound Paclitaxel × Clear all

NCT04251533 2026-04-03

EPIK-B3

Phase 3 Terminated

137 enrolled 21 charts

Triple Negative Breast Neoplasms

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT01834235 2025-05-07

QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

Phase 1/2 Terminated

81 enrolled 13 charts

Gastrointestinal

Pancreatic cancer, adult, Pancreatic Neoplasms

NCT03009058 2024-11-25

MODULATE

Phase 1/2 Terminated

2 enrolled 7 charts

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT03435250 2024-07-25

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Phase 1 Terminated

Lymphoma

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Phase 3 Terminated

8 enrolled 7 charts

NSCLC

NCT04761601 2024-03-13

First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumor

NCT04329949 2023-11-18

RELIANT

Phase 3 Terminated

43 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04983407 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Phase 1/2 Terminated

Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03138889 2023-03-10

PROPEL

Phase 1/2 Terminated

162 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

Phase 2 Terminated

Breast Neoplasms

NCT04060342 2022-08-18

GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma

Phase 1 Terminated

BreastGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04210037 2022-07-12

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Phase 1/2 Terminated

Small Cell Lung Carcinoma

NCT01461915 2022-06-06

PGPC1

Phase 2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

Phase 1 Terminated

BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02715804 2020-07-14

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Phase 3 Terminated

492 enrolled 16 charts

Gastrointestinal

Neoplasm Metastasis, Carcinoma, Pancreatic Ductal

NCT01836432 2020-05-28

PILLAR

Phase 3 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1/2 Terminated

83 enrolled 31 charts

Neoplasm Metastasis

NCT00140140 2019-11-26

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Phase 1/2 Terminated

16 enrolled 21 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00281528 2019-11-22

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Phase 2 Terminated

208 enrolled 23 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00456846 2019-11-22

First Line Therapy for Patients With Metastatic Breast Cancer

Phase 2 Terminated

123 enrolled 19 charts

Breast Neoplasms

NCT02267707 2019-11-01

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Phase 1 Terminated

Gastrointestinal

Cholestasis, Pancreatic Neoplasms

NCT00407407 2019-10-18

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Phase 1 Terminated

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02570711 2019-08-28

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Phase 2 Terminated

3 enrolled 10 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01376310 2019-02-19

GSK1120212 Rollover Study

Phase 2 Terminated

159 enrolled 9 charts

Neoplasms

NCT02109445 2019-01-10

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Phase 2 Terminated

3 enrolled 15 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01621243 2018-08-29

M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Phase 1/2 Terminated

Gastrointestinal

Pancreatic Neoplasms

NCT01929941 2018-01-17

An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies

Phase 1 Terminated

BreastGastrointestinalLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Pancreatic Neoplasms